Physiologisches Institut der Christian-Albrechts-Universität zu Kiel, Germany.
Nephrol Dial Transplant. 2012 Oct;27(10):3790-8. doi: 10.1093/ndt/gfs107. Epub 2012 May 4.
Carbamazepine (CBZ) is a drug widely used in the therapy of epilepsy and mood disorders. One frequently observed side effect is hyponatraemia. The role of vasopressin in hyponatraemic action of CBZ is discussed controversially. In this study, we tested the influence of CBZ on water and salt homoeostasis in rat under different hydration states and under vasopressin 2 receptor (V2R) antagonism by satavaptan to elucidate the renal and vasopressin independent action of CBZ.
CBZ-treated rats were investigated on metabolic cages after (i) 6 day with ad libitum fluid intake, (ii) moderate water load and (iii) water restriction. The effect of satavaptan was tested in clearance experiments under continuous saline infusion in anaesthetized rats after CBZ pretreatment.
Compared to controls, CBZ induced a higher urinary flow rate which was most pronounced (20-fold) after water load and significantly elevated (2-fold) after 10-h water restriction. In addition, CBZ consistently increased renal sodium loss but failed to decrease plasma sodium concentration. In the presence of satavaptan, urinary flow and natriuresis were further increased by CBZ, while there was no differential effect on urea excretion and anion gap.
At the investigated dose (50 mg/kg body weight), CBZ did not induce hyponatraemia or antidiuresis in the rat. However, depending on the hydration state, it induced an increased water and electrolyte loss. Its enhanced influence on urinary flow and natriuresis in the presence of satavaptan suggests additional renal targets for CBZ, independent of vasopressin signalling.
卡马西平(CBZ)是一种广泛用于治疗癫痫和情绪障碍的药物。一种常见的副作用是低钠血症。关于 CBZ 对低钠血症作用的血管加压素作用存在争议。在这项研究中,我们在不同的水合状态下和使用 satavaptan 拮抗血管加压素 2 受体(V2R)的情况下,测试了 CBZ 对大鼠水盐稳态的影响,以阐明 CBZ 的肾和血管加压素独立作用。
在(i)6 天自由饮水、(ii)适度水负荷和(iii)限水后,对 CBZ 处理的大鼠进行代谢笼研究。在 CBZ 预处理后,在麻醉大鼠连续盐水输注下进行清除实验,测试 satavaptan 的作用。
与对照组相比,CBZ 诱导的尿流量更高,在水负荷后最为明显(20 倍),在 10 小时限水后显著升高(2 倍)。此外,CBZ 一致增加了肾钠丢失,但未能降低血浆钠浓度。在 satavaptan 的存在下,CBZ 进一步增加了尿流量和排钠,但对尿素排泄和阴离子间隙没有差异影响。
在所研究的剂量(50mg/kg 体重)下,CBZ 不会在大鼠中引起低钠血症或抗利尿作用。然而,根据水合状态,它会引起水和电解质的增加丢失。在 satavaptan 的存在下,它对尿流量和排钠的增强影响表明 CBZ 有额外的肾靶标,与血管加压素信号无关。